95
TRANSFORM-HF - A large-scale , pragmatic , randomized , unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure . Principal investigator : Melody Sherwood , MD .
TRIFECTA-HEART - Trifecta-Heart cfDNA-MMDx study comparing the dd-cfDNA test to MMDx microarray test and central HLA antibody test . Principal investigator : Shelley Hall , MD .
TRILUMINATE - A randomized , controlled trial to demonstrate the safety and effectiveness of the TriClip device in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation ( TR ), who are at intermediate or greater estimated risk for mortality with tricuspid valve surgery . The study compares the TriClip device to control medical therapy . Principal investigator : James Choi , MD .
TROJAN-C - This phase II , multi-center , open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCVnegative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg ( Epclusa ® ). Principal investigator : Robert Gottlieb , MD , PhD .
UMBRELLA HEART - Protocol to conduct a broad range of retrospective data reviews on heart transplant , lung transplant , ventricular assist devices ( VADs ), advanced heart failure and cardiology . Principal investigator : Dan Meyer , MD .
UMBRELLA NATIONAL / REGIONAL DATABASES - Umbrella National Inpatient Sample Database Protocol . Principal investigator : Shelley Hall , MD .
VAREE - The variability of donor-derived cellfree DNA after heart transplantation . Principal investigator : Timothy Gong , MD .
VASCC PROJECT 2 - The study will look at various outcomes , including but not limited to in-hospital complications and adverse events related to the patterns of hematologic changes among COVID-19 patients . The study will also aim to identify various management practices among a diverse group of vascular surgeons around the world and correlate with patient outcomes . Principal investigator : John Eidt , MD .
VELOXIS ENVARSUS - A phase II study evaluating the efficacy of tacrolimus extended release tablets to twice daily tacrolimus dosing regimen . Twenty-five adult recipients of a heart transplant will be enrolled in each group ― one receiving a once a day dosing of Envarsus , the other receiving twice a day dosing of Prograf . Results of the two groups will be compared and evaluated for short-term safety and tolerability of Envarsus . Principal investigator : Shelley Hall , MD .
XIENCE 90 - The objective of this trial is to evaluate safety of three-months dual antiplatelet therapy ( DAPT ) in subjects at high risk of bleeding ( HBR ) undergoing percutaneous coronary intervention ( PCI ) with XIENCE . Principal investigator : James Choi , MD .
Cardiologists involved in treatment options targeting COVID-19
Cardiologists on the medical staff continued involvement in targeted studies related to COVID-19 . Using experience with specific medications , several heart specialists participated in national clinical trials and studies focused on identifying ways to slow or lessen the severity of COVID-19 illness in patients . As the pandemic continued , researchers recognized how profoundly COVID-19 can and does affect patients and their cardiac health leading to participation in numerous studies investigating how COVID-19 affects the cardiovascular system and the long-term implications of having had the disease both physically and psychologically .
Recent studies from our investigators provide crucial new data on how to combat severe manifestations of COVID-19 in at-risk populations , and addressed the pressing need for therapies with continued efficacy upon the emergence of the Omicron variant of SARS-CoV-2 .
Robert L . Gottlieb , MD , PhD , FACC , FIDSA , researcher and advanced heart failure and transplant cardiologist on the medical staff of Baylor Scott & White Heart and Vascular Hospital - Dallas and Baylor University Medical Center , was the lead author on the findings from the multi-center , international randomized clinical trial investigating the use of intravenous remdesivir in the outpatient setting to prevent severe COVID-19 illness or hospitalization in high-risk populations who test positive and are symptomatic .
Baylor Scott & White Heart and Vascular Hospital | Clinical Trials and Research